Nolan explores the potential of ibogaine and its metabolites in treating human illnesses while addressing the associated cardiac risks. He emphasizes the importance of safety measures, like administering IV magnesium, to mitigate these risks during treatment. With a notable track record of safe operations in Mexico, the conversation sheds light on the evolving landscape of psychedelic therapies and their implications for patient care.
